Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The elucidation of species-specific receptor pharmacology: a case study using subtype selective para- and meta-carborane estrogen receptor agonists.
Adeluola AA, Radomska HS, Wilson TA, Kulp SK, Kabat A, Helms TH, Mayo AK, Montgomery EJ, Thomas J, Marcho LM, Costa T, Fukuda M, Kang DD, Vibhute S, Wang D, Bennett CE, Coss CC. Adeluola AA, et al. Among authors: kulp sk. J Pharmacol Exp Ther. 2024 Jun 27:JPET-AR-2023-001874. doi: 10.1124/jpet.123.001874. Online ahead of print. J Pharmacol Exp Ther. 2024. PMID: 38936980 Free article.
Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans.
Castillo AMM, Vu TT, Liva SG, Chen M, Xie Z, Thomas J, Remaily B, Guo Y, Subrayan UL, Costa T, Helms TH, Irby DJ, Kim K, Owen DH, Kulp SK, Mace TA, Phelps MA, Coss CC. Castillo AMM, et al. Among authors: kulp sk. JCSM Rapid Commun. 2021 Jul-Dec;4(2):232-244. doi: 10.1002/rco2.32. Epub 2021 Feb 9. JCSM Rapid Commun. 2021. PMID: 34514376 Free PMC article.
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.
Vu TT, Kim K, Manna M, Thomas J, Remaily BC, Montgomery EJ, Costa T, Granchie L, Xie Z, Guo Y, Chen M, Castillo AMM, Kulp SK, Mo X, Nimmagadda S, Gregorevic P, Owen DH, Ganesan LP, Mace TA, Coss CC, Phelps MA. Vu TT, et al. Among authors: kulp sk. Pharmacol Res. 2024 Jan;199:107048. doi: 10.1016/j.phrs.2023.107048. Epub 2023 Dec 23. Pharmacol Res. 2024. PMID: 38145833 Free PMC article.
Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma.
Omar HA, Sargeant AM, Weng JR, Wang D, Kulp SK, Patel T, Chen CS. Omar HA, et al. Among authors: kulp sk. Mol Pharmacol. 2009 Nov;76(5):957-68. doi: 10.1124/mol.109.058180. Epub 2009 Aug 25. Mol Pharmacol. 2009. PMID: 19706731 Free PMC article.
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS. Weng SC, et al. Among authors: kulp sk. Mol Cancer Ther. 2008 Apr;7(4):800-8. doi: 10.1158/1535-7163.MCT-07-0434. Mol Cancer Ther. 2008. Retraction in: Mol Cancer Ther. 2019 Apr;18(4):869. doi: 10.1158/1535-7163.MCT-19-0151 PMID: 18413793 Retracted.
The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.
Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, Chang H, Castillo AMM, Chen M, Remaily B, Kim K, Xie Z, Dillhoff ME, Kulp SK, Behbehani GK, Cruz-Monserrate Z, Ganesan LP, Owen DH, Phelps MA, Coss CC, Mace TA. Thomas J, et al. Among authors: kulp sk. Int J Mol Sci. 2022 Jun 25;23(13):7066. doi: 10.3390/ijms23137066. Int J Mol Sci. 2022. PMID: 35806069 Free PMC article.
Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models.
Kaweesa EN, Bazioli JM, Pierre HC, Lantvit DD, Kulp SK, Hill KL, Phelps MA, Coss CC, Fuchs JR, Pearce CJ, Oberlies NH, Burdette JE. Kaweesa EN, et al. Among authors: kulp sk. Mol Pharm. 2023 Jun 5;20(6):3049-3059. doi: 10.1021/acs.molpharmaceut.3c00069. Epub 2023 May 8. Mol Pharm. 2023. PMID: 37155928 Free PMC article.
130 results